Avita Medical Ltd. (AVMXY: OTCQX International) | Avita Medical to Participate in the 3rd annual Biotech and Money / Medtech and Money London 2017 Conference

Avita Medical to Participate in the 3rd annual Biotech and Money / Medtech and Money London 2017 Conference
Jan 24, 2017
OTC Disclosure & News Service
Northridge, CA, Perth, Australia and London, United Kingdom

 Avita Medical Ltd
(ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specializing in new
treatments for wounds and skin defects, said today that Adam Kelliher, Avita’s
Chief Executive Officer, will be a panel member at the Biotech and Money /
Medtech and Money conference taking place in London, UK on 7-8 February, 2017.

The 3rd annual Biotech and Money / Medtech and Money London
is a two-day conference and partnering event providing the education,
strategies, solutions and contacts that life science companies need to enable
more effective funding, investment, business planning and partnering within
their businesses.  The conference is a
senior level educational, best practices and networking event that  includes keynote panels with leading life
science funds, discussion groups and the opportunity to participate in 1×1

Panel details:
Title:                     Anatomy of a Medtech private financial raise
Date:                     Wednesday, 8 February, 2017
Time:                    11:20 GMT
Location:             etc. venues, 155 Bishopsgate,
London, EC2M 4AN, United Kingdom
“With over 400 attendees including over 150 investors, we
are able to connect with industry leaders and top life science investors to
disccuss Avita’s commercial, regulatory, scientific and clinical research
developments across the range of indications for which the Company’s portfolio
of products (ReCell®, ReGenerCellâ„¢ and ReNovaCellâ„¢) are in use around the world,â€
stated Mr. Kelliher.
Avita Medical develops and
distributes regenerative products for the treatment of a broad range of wounds,
scars and skin defects. Avita’s patented and proprietary collection and
application technology provides innovative treatment solutions derived from a
patient’s own skin. The Company’s lead product, ReCell®, is used in the
treatment of a wide variety of burns, plastic, reconstructive and cosmetic
procedures. ReCell® is patented, CE-marked for Europe, TGA-registered in
Australia, and CFDA-cleared in China. In the United States, ReCell® is an
investigational device limited by federal law to investigational use, and a
pivotal U.S. approval trial is underway. To learn more, visit

This release includes additional documents. Select the link(s) below to view.
Avita Medical to Present at Biotech and Money Medtech and Money Conference.pdf
Copyright © 2017 OTC Markets. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Most Popular

To Top